Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials

Regan Meredith M.; Francis Prudence A.; Pagani Olivia; Fleming Gini F.; Walley Barbara A.; Viale Giuseppe; Colleoni Marco; Lang Istvan; Gomez Henry L.; Tondini Carlo; Pinotti Graziella; Price Karen N.; Coates Alan S.; Goldhirsch Aron; Gelber Richard D.

首页> 外文期刊>Journal of Clinical Oncology >Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials

【24h】

Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials

机译：激素受体阳性，人表皮生长因子受体2阴性的绝经前妇女辅助内分泌治疗的绝对优势：TEXT和SOFT试验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2016年第19期|共13页
作者
Regan Meredith M.; Francis Prudence A.; Pagani Olivia; Fleming Gini F.; Walley Barbara A.; Viale Giuseppe; Colleoni Marco; Lang Istvan; Gomez Henry L.; Tondini Carlo; Pinotti Graziella; Price Karen N.; Coates Alan S.; Goldhirsch Aron; Gelber Richard D.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials [J] . Regan Meredith M., Francis Prudence A., Pagani Olivia, Journal of Clinical Oncology . 2016,第19期

机译：激素受体阳性，人表皮生长因子受体2阴性的绝经前妇女辅助内分泌治疗的绝对优势：TEXT和SOFT试验
2. Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): additional results from the MONALEESA-7 trial [J] . Harbeck N., Vazquez R. Villanueva, Tripathy D., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：Ribociclib（肋骨）加入莫昔芬（TAM）或非甾体芳香酶抑制剂（NSAI）在具有激素受体阳性（HR加），人表皮生长因子受体2阴性（HER2-）晚期乳腺癌（ABC）：Monaleesa-7试验的其他结果
3. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3 [J] . Cristofanilli Massimo, DeMichele Angela, Giorgetti Carla, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：Palbociclib Palbociclib的延长福利预测因子在Paloma-3中具有内分泌抗性激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌的妇女
4. Identification of Human Epidermal Growth Factor Receptor 2 Antagonist In Silico for Breast Cancer Therapy, Derived from Indonesian Phytochemicals [C] . Tuti Ratnasari, Dono indarto, Raden Ajeng Sri Wulandari, International Conference on Biomedical Engineering . 2018

机译：人类表皮生长因子受体2拮抗剂在二氧化硅中用于印尼治疗的印尼植物化学成分的鉴定。
5. Treatment Interruption and Discontinuation of Hormone Therapy in Hormone Receptor-Positive Breast Cancer Patients [D] . Mao, Daqin . 2020

机译：激素受体阳性乳腺癌患者中的治疗中断与激素治疗中的中断和停止
6. Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: TEXT and SOFT Trials [O] . Meredith M. Regan, Prudence A. Francis, Olivia Pagani, -1

机译：绝经前妇女接受激素受体阳性人表皮生长因子受体2阴性早期乳腺癌的辅助内分泌疗法的绝对益处：TEXT和SOFT试验
7. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative early breast cancer: TEXT and SOFT Trials [O] . Regan, Meredith M., Francis, Prudence A., Pinotti, Graziella, 2016

机译：辅助内分泌疗法对绝经前激素受体阳性，人表皮生长因子受体2阴性的早期乳腺癌的绝对益处：TEXT和SOFT试验

Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅